
Opinion|Videos|December 23, 2024
Thoughts on the Current State of PBC Management
Key Takeaways
- PBC involves autoimmune-mediated destruction of intrahepatic bile ducts by autoreactive T lymphocytes, leading to cholestasis.
- Accumulation of toxic bile acids due to cholestasis causes hepatocellular damage and inflammation.
The panel of experts offers expert insights and concluding thoughts on the management of primary biliary cholangitis (PBC), emphasizing the importance of personalized treatment strategies, monitoring, and the evolving role of new therapies in improving patient outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please share your concluding thoughts about management of PBC.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
APPs on the Frontline of AATD Management, With Sarah Tomashefski, MSN
2
Positioning New Agents and Overcoming Real-World Barriers for Asthma and COPD
3
Phase 3 Data Indicate Roflumilast Cream Benefit Extend to Youngest Atopic Dermatitis Patients
4
RAD 2026: Tralokinumab Improves Hand AD Outcomes, Outperforms Dupilumab in MAIC
5




























































